Company / Return on Equity (ROE)
Minerva Neurosciences, Inc. Return on Equity (ROE) History
FY2017-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-625.7%
FY2022
5-year range
-625.7% / 3.7%
FY2018-FY2022
Trend
-17057.5%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Minerva Neurosciences, Inc. reports negative total equity of -625.7% in FY2022. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-625.7% in FY2022 with a 5-year CAGR of -600.2%.
Declined from -259.8% to -625.7% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -570.1pp
- 5-Year Change
- -600.2pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2022, return on equity (roe) decreased 17057.5% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -10.64 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -625.7% | -17057.5% |
| FY2021 | 3.7% | +101.4% |
| FY2020 | -259.8% | -367.5% |
| FY2019 | -55.6% | -132.1% |
| FY2018 | -23.9% | +6.3% |
| FY2017 | -25.6% | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026